Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
The Phase II PONTIAK study aims to evaluate the efficacy of cilastatin in preventing AKI associated with nephrotoxic pharmaceuticals, which include commonly used drugs such as antibiotics, chemotherapy agents, and imaging dyes, some of which are known to cause kidney damage as a side effect. The trial plans to enrol approximately 698 patients in five hospital sites in Alberta.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
4 hours ago
- Toronto Star
Pacific Green Signs Commitment Agreement With ZEN Energy for BESS Offtake in Australia for 1.5GWh
Sydney, Aug. 05, 2025 (GLOBE NEWSWIRE) — - Pacific Green is pleased to announce that its battery energy storage business in Australia has entered into a commitment agreement with ZEN Energy ('ZEN') for 10-year tolling arrangements across three Battery Energy Storage System (BESS) projects located in Victoria, New South Wales, and Queensland totaling 1.5GWh of storage capacity. This milestone marks a pivotal step in Pacific Green's transition to its next phase of growth, significantly accelerating the route to market for its Australian project portfolio of 7GWh. Scott Poulter, Pacific Green's Group CEO, commented: 'Following our initial offtake agreement of 500MWh for Limestone Coast North in South Australia, we are delighted to enter into a strategic framework for a further 1.5GWh. This framework agreement helps Pacific Green underwrite a significant part of the our portfolio of developments in Victoria, New South Wales and Queensland, and enables Pacific Green to industrialize its project development processes.'
Toronto Star
6 hours ago
- Toronto Star
James River Announces Second Quarter 2025 Results
PEMBROKE, Bermuda, Aug. 04, 2025 (GLOBE NEWSWIRE) — James River Group Holdings, Ltd. ('James River' or the 'Company') (NASDAQ: JRVR) reported net income from continuing operations available to common shareholders of $3.2 million ($0.07 per diluted share) and adjusted net operating income1 of $11.7 million ($0.23 per diluted share) for the second quarter of 2025. Unless specified otherwise, all underwriting performance ratios presented herein are for our continuing operations and business not subject to retroactive reinsurance accounting.
Toronto Star
6 hours ago
- Toronto Star
EXP joins Manatee County to celebrate the completion of the 44th Ave East Extension Project
BRADENTON, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) — EXP joined Manatee County officials, the Florida Department of Transportation, SEMA Construction and community members to celebrate the official opening of the 44th Avenue Extension Project. The 44th Avenue East Extension Project will increase road capacity for more vehicles daily, provide alternative routes for local traffic and improve traffic capacity. The opening marks the successful completion of the six-phase project undertaken by Manatee County.
